Psychiatry

Prescription rates of buprenorphine and opioid analgesics for OUD fell during the COVID-19 pandemic for new patients, but existing treatment was not affected.

Dr. Todd Hutton gives tips for how to best handle the ongoing mental health crisis.

A recent JAMA study shows a decrease in suicide deaths between 2019-2020, despite a 17% overall increase in mortality.

Approximately 30% of schizophrenia patients do not respond to their first treatment.

Andrew J. Cutler, MD discusses new research into the efficacy and safety of a D-ATS treatment in children with ADHD.

Clozapine is considered the gold standard of schizophrenia treatment.

Education could be the best resource in increasing prescription rates for clozapine.

Data show zolpidem use in 8-week insomnia trial reduced suicidal ideation in patients, even after trial randomization ended.

New data show high rate of depressive symptoms in patients with NTFE schizophrenia.

Impaired reward processing could influence the presentation of sleep disturbances for patients with ADHD.

Adults often do not suffer from the symptoms of hyperactivity in ADHD.

New data show adverse childhood experiences can cause personality changes proximal to trauma, rather than developing later in life.

New data show ADHD-specific text message intervention beneficial to patients who may have low rate of stimulant treatment adherence.

While treatment options do not impact 30-day readmissions, they can influence hospital length of stay and costs.

Data show effectiveness of DSRM in treating major depressive disorder with less frequent discontinuations.

More research is needed to fully understand the associations with different types of strabismus

Late life depression is a known risk factor for dementia, impacting 8-16% in the US.

New data show mental health workers experienced lower levels of traumatic stress and peritraumatic distress during COVID-19 pandemic, compared to healthcare workers and general population.

The transition from pediatric care to adult care can be confusing for ADHD patients, often leading to a discontinuation of health care services altogether.

Despite higher risk of adverse effects in patients with opioid use disorder, benzodiazepine does not undo protection benefits of buprenorphine.

In a poster presented at APA, researchers review current clinical practice guidelines for schizophrenia.

New data show significant therapeutic effects of dextraomethadone treatment in MDD patients below the median percentage of life-years from diagnosis.

A new study from APA 2021 finds algorithm use can reduce clinical misdiagnosis of bipolar disorder as other mood disorders, including major depressive disorder.

The rates of both diseases have been increasingly linked in recent years.

Dr. Joshua Morganstein discusses the psychological impacts disasters can have on individuals and how the COVID-19 pandemic might be different than other disasters.